1-{3-[4-amino-7-(3-hydroxymethylphenyl)-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}pyrrolidin-2-one | 723265-41-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-{3-[4-amino-7-(3-hydroxymethylphenyl)-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}pyrrolidin-2-one
• 英文别名: 1-[3-[4-Amino-7-[3-(hydroxymethyl)phenyl]-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]propyl]pyrrolidin-2-one
• CAS: 723265-41-6
• 化学式: C₂₇H₃₁N₅O₃
• 分子量: 473.575
• InChiKey: MGMXVXYXMURFGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  35
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  107
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Compositions for stimulation of mammalian innate immune resistance to pathogens
  申请人：The Board of Regents, The University of Texas System

  公开号：US10722573B2

  公开（公告）日：2020-07-28

  Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a StIR composition to the individual.

  本发明的实施方案涉及治疗、抑制或减弱已感染或有感染风险的个体的微生物感染的方法，包括向该个体施用有效量的 StIR 组合物的步骤。
• FORMULATIONS CONTAINING AN IMMUNE RESPONSE MODIFIER
  申请人：3M Innovative Properties Company

  公开号：EP1651190B1

  公开（公告）日：2012-09-19
• COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS
  申请人：The Board of Regents of The University of Texas System

  公开号：EP2411521A1

  公开（公告）日：2012-02-01
• METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION
  申请人：THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

  公开号：US20190269773A1

  公开（公告）日：2019-09-05

  Embodiments are directed to methods and compositions for modulating an immune response. In certain aspects the immune response is a type I hypersensitivity response. In particular aspects the subject has allergic asthma or allergic rhinitis. Using a conventional experimental asthma mouse model (BALB/c), the inventors demonstrate that aerosol administration of TLR agonists, in particular a combination of TLR2/6 and TLR9 agonist (e.g., TLR9 oligonucleotide agonist/PAM2CSK4) along with an antigen (e.g., ovalbumin (OVA)) suppresses the immune response as exemplified by the production of antigen-specific IgE and decreases the number of airway eosinophils in bronchoalveolar lavage fluid (BAL) in response to intraperitoneal (IP) immunization with an antigen mixed with alum.
• US8883174B2
  申请人：——

  公开号：US8883174B2

  公开（公告）日：2014-11-11